
Please try another search
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Sandra L. Silberman | 65 | 2017 | Member of Clinical Advisory Board |
Filip Janku | 47 | - | Member of Clinical Advisory Board |
Emmanuel Antonarakis | - | 2020 | Member of Clinical Advisory Board |
Mark Erlander | 61 | 2013 | CEO & Director |
Rodney S. Markin | 64 | 2014 | Independent Chairman of the Board |
Gary W. Pace | 73 | 2020 | Independent Director |
Renee P. Tannenbaum | 70 | 2021 | Independent Director |
Lale White | 66 | 2020 | Independent Director |
Carlo Maria Croce | - | - | Member of Scientific Advisory Board |
Paul R. Billings | 70 | 2012 | Member of Scientific Advisory Board |
Charles R. Cantor | 79 | - | Member of Scientific Advisory Board |
Michael B. Yaffe | - | 2018 | Member of Clinical Advisory Board |
Glenn J. Bubley | - | 2018 | Member of Clinical Advisory Board |
Heinz-Josef Lenz | 62 | 2020 | Member of Clinical Advisory Board |
Alberto Bardelli | - | 2014 | Member of Scientific Advisory Board |
Brunangelo Falini | - | 2010 | Member of Scientific Advisory Board |
K. Peter Hirth | 70 | 2014 | Member of Scientific Advisory Board |
James O. Armitage | 75 | 2020 | Independent Director |
Mani Mohindru | 50 | 2021 | Independent Director |
Amer Zeidan | - | 2020 | Member of Clinical Advisory Board |
Riccardo Dalla-Favera | 70 | 2010 | Member of Scientific Advisory Board |
David Einstein | - | 2018 | Member of Clinical Advisory Board |
Adam Schayowitz | - | - | Member of Scientific Advisory Board |
Christoph Reinhard | - | - | Member of Scientific Advisory Board |
Nicholas Choong | - | 2024 | Member of the Scientific Advisory Board |
Josep Tabernero Caturla | - | - | Member of Scientific Advisory Board |
Eric Van Cutsem | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review